Madrigal Pharmaceuticals

Madrigal reported Q2 2026 revenue of $364 million (+71% y/y) and trailing twelve‑month revenue of about $1.3 billion; the number of active Rezdiffra patients is over 50,000. The company is building a pipeline of ten active compounds that were prepaid for less than $300 million and plans three combination studies with Resmetirom for 2027. Management views Rezdiffra as a backbone therapy with potential for indication expansions up to cirrhotic stages; patent protection runs through 2045. European revenues are likely to be constrained in 2026 due to price controls. » More on de.investing.com

Shareholders of Madrigal Pharmaceuticals voted in favor of the 2026 Stock Plan and the 2026 Employee Stock Purchase Plan, as well as a non-qualified deferred compensation plan for executive officers and outside directors that becomes effective August 1, 2026. Dr. Rebecca Taub will move to an advisory role on July 1, 2026, remains a class II director, and Julian C. Baker, Daniel J. Brennan and James M. Daly were reclassified/confirmed as class I directors. The company retained PricewaterhouseCoopers as auditor and received, on a non-binding basis, shareholder approval of executive compensation. Madrigal reported better-than-expected Q1 2026 results (EPS -$3.25; revenue $311.3 million) and saw mixed analyst reactions to Rezdiffra with price targets ranging from $542 to $737; the stock trades at $499.86 and is estimated to remain below fair value. » More on de.investing.com

The UK medicines regulator MHRA has approved Madrigal’s resmetirom (Rezdiffra) for the treatment of adults with nonalcoholic steatohepatitis (NASH) and moderate to advanced fibrosis. Resmetirom acts via the thyroid hormone receptor beta (THR-β) and reduces liver fat, inflammation and scarring; common side effects are diarrhea and nausea. The approval supports the stock; Madrigal will present next week at the Goldman Sachs Health Care Conference and plans to report pivotal cirrhosis data in 2026. » More on deraktionaer.de